{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:49:45Z","timestamp":1790272185360,"version":"4.1.0"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:p>Multiple myeloma (MM) represents an incurable hematologic malignancy. Despite significant advances over the past decade, with the advent of multiple new classes of anti-myeloma agents, including immunomodulatory drugs, proteasome inhibitors and monoclonal antibodies, patients ultimately relapse. Selinexor is a first-in-class exportin-1 inhibitor with activity in these multiply relapsed and refractory patients. Although the current Food and Drug Administration (FDA) approval is for the doublet of Selinexor in combination with dexamethasone, ongoing clinical trials are evaluating a number of combination regimens. These triplet and quadruplet, selinexor-based, regimens are showing significant activity in \u201ctriple-class\u201d refractory patients. With appropriate combination drug choice, drug dosing, and supportive measures, patients with previously no viable options for therapy, now have multiple potential regimens to control their disease.<\/jats:p>","DOI":"10.1177\/2040620720930629","type":"journal-article","created":{"date-parts":[[2020,6,9]],"date-time":"2020-06-09T07:27:57Z","timestamp":1591687677000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":49,"title":["Selinexor in relapsed\/refractory multiple myeloma"],"prefix":"10.1177","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0274-0585","authenticated-orcid":false,"given":"Joshua","family":"Richter","sequence":"first","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Tisch Cancer Institute Ringgold Standard Institution \u2013 Hematology\/Oncology, 1 Gustave L. Levy Pl., New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepu","family":"Madduri","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Tisch Cancer Institute Ringgold Standard Institution \u2013 Hematology\/Oncology, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shambavi","family":"Richard","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Tisch Cancer Institute Ringgold Standard Institution \u2013 Hematology\/Oncology, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajai","family":"Chari","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai Tisch Cancer Institute Ringgold Standard Institution \u2013 Hematology\/Oncology, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2020,6,9]]},"reference":[{"key":"bibr1-2040620720930629","unstructured":"National Center Institute: Surveillance, Epidemiology, and End Results Program. Cancer stat facts: myeloma, https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html (accessed 23 December 2019)."},{"key":"bibr2-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.08.011"},{"key":"bibr3-2040620720930629","unstructured":"U.S. Food and Drug Administration. FDA grants accelerated approval to selinexor for multiple myeloma, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-selinexor-multiple-myeloma (accessed 23 December 2019)."},{"key":"bibr4-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"bibr5-2040620720930629","unstructured":"XPOVIO\u2122 (selinexor). Karyopharm Therapeutics Inc. Newton, MA, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/212306s000lbl.pdf (accessed 23 December 2019)."},{"key":"bibr6-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858852"},{"key":"bibr7-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15261"},{"key":"bibr8-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2014.11.019"},{"key":"bibr9-2040620720930629","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12969"},{"key":"bibr10-2040620720930629","unstructured":"Karyopharm Therapeutics Inc. Karyopharm announces phase 3 BOSTON study meets primary endpoint with significant increase in progression-free survival in patients with multiple myeloma following one to three prior lines of therapy, https:\/\/www.globenewswire.com\/news-release\/2020\/03\/02\/1993339\/0\/en\/Karyopharm-Announces-Phase-3-BOSTON-Study-Meets-Primary-Endpoint-with-Significant-Increase-in-Progression-Free-Survival-in-Patients-with-Multiple-Myeloma-Following-One-to-Three-Pri.html (accessed 23 March 2020)."},{"key":"bibr11-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.2913.2913"},{"key":"bibr12-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0488"},{"key":"bibr13-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15969"},{"key":"bibr14-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"bibr15-2040620720930629","volume-title":"Presented at the EHA 2019 Annual Meeting","author":"Gasparetto C","year":"2019"},{"key":"bibr16-2040620720930629","volume-title":"Presented at the EHA 2019 Annual Meeting","author":"Gasparetto C"},{"key":"bibr17-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122907"},{"key":"bibr18-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"bibr19-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31240-1"},{"key":"bibr20-2040620720930629","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123465"},{"key":"bibr21-2040620720930629","volume":"134","author":"Nishihori T","year":"2019","journal-title":"Blood"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620720930629","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2040620720930629","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2040620720930629","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:14:56Z","timestamp":1777590896000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2040620720930629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":21,"alternative-id":["10.1177\/2040620720930629"],"URL":"https:\/\/doi.org\/10.1177\/2040620720930629","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"article-number":"2040620720930629"}}